An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Nature medicine, 2022•nature.com
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody
countermeasure efficacy because of the number of mutations in the spike protein. In this
study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs)
corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-
7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody
countermeasure efficacy because of the number of mutations in the spike protein. In this
study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs)
corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-
7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of …
Abstract
The emergence of the highly transmissible B.1.1.529 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. In this study, we tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Eli Lilly (LY-CoV555 and LY-CoV016) and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987 and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use might lose efficacy against the B.1.1.529 Omicron variant.
nature.com
